Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Status:
RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
To evaluate the feasibility, effectiveness and safety of chidamide combined with venetoclax and azacitidine in the treatment of newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy.
Phase:
NA
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China